{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:12:04Z","timestamp":1751461924460},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejca.2024.114097","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T01:37:22Z","timestamp":1715045842000},"page":"114097","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma"],"prefix":"10.1016","volume":"205","author":[{"given":"Sara Elena","family":"Rebuzzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114097_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114048","article-title":"Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma","author":"Carril-Ajuria","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2024.114097_bib2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2024.114097_bib3","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3390\/cancers11111713","article-title":"The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors","volume":"11","author":"Meyers","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.114097_bib4","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211019642","article-title":"Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)","volume":"13","author":"Rebuzzi","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2024.114097_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221079580","article-title":"Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib","volume":"14","author":"Rebuzzi","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.114097_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100634","article-title":"Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program","volume":"7","author":"Rebuzzi","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ejca.2024.114097_bib7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clgc.2023.10.001","article-title":"Prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib: a subanalysis of the prospective ZEBRA study (Meet-URO 9)","volume":"22","author":"Damassi","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2024.114097_bib8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12967-024-05014-z","article-title":"Validation of the Meet-URO score in metastatic clear cell renal cell carcinoma patients receiving second or third-line tyrosine kinase inhibitors-immune checkpoint inhibitors combination therapy","volume":"22","author":"He","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2024.114097_bib9","doi-asserted-by":"crossref","unstructured":"Rebuzzi SE, Fornarini G, Signori A, et al. International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma \u2013 Meet-URO 33 study (REGAL study). BMC Cancer (preprint); 2024. \u3008https:\/\/doi.org\/10.21203\/rs.3.rs-3419200\/v1\u3009. [In press].","DOI":"10.21203\/rs.3.rs-3419200\/v1"},{"key":"10.1016\/j.ejca.2024.114097_bib10","unstructured":"Study design of the CARE-1 RLT trial is available at: \u3008https:\/\/www.urotoday.com\/conference-highlights\/asco-2023\/asco-2023-kidney-cancer\/145009-asco-2023-doublet-and-triplet-therapy-for-metastatic-rcc-the-case-for-doublet-therapy.html\u3009."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924007536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T02:59:33Z","timestamp":1726023573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924007536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":10,"alternative-id":["S0959804924007536"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114097","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114048","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114097"}}